Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

8:35 AM ET 8-K
Leadership Change Newell Brands Inc. NWL

Newell Brands Leadership Change

Newell Brands has elected William Newlands, the former President and CEO of Constellation Brands, to its Board of Directors, effective January 1, 2027. The appointment will increase the size of the Board from eight to nine members, with Newlands set to serve on the Audit and Compensation committees. The move adds significant consumer brand-building and public company governance experience to the board.

Counterparty
William Newlands
8:34 AM ET 8-K
Business Update Vistagen Therapeutics, Inc. VTGN

Vistagen Therapeutics Business Update

Vistagen announced a productive Type C meeting with the FDA regarding the Phase 3 development path for its lead candidate, fasedienol, in social anxiety disorder (SAD). The FDA provided constructive feedback on using the Liebowitz Social Anxiety Scale (LSAS) as a primary endpoint and recommended incorporating interim assessments to evaluate long-term functional improvement.

Counterparty
FDA
8:33 AM ET 10-Q
Financial Results Ionis Pharmaceuticals Inc IONS

Ionis Pharmaceuticals Q3 2026 Results: Net Loss of $110M, Loss Narrows

For the nine months ended September 30, 2026, Ionis Pharmaceuticals reported total revenue of $756.8 million, a slight increase from $740.4 million in the prior year, driven by higher commercial product sales. However, the company's net loss widened significantly to $317.1 million compared to $152.0 million in 2025, primarily due to a substantial increase in selling, general, and administrative expenses.

Key figure
Net loss $110M
8:31 AM ET 8-K
Clinical Trial Data Vir Biotechnology, Inc. VIR

Vir Biotechnology Clinical Trial Data

Vir Biotechnology announced positive topline results from its pivotal Phase 3 ECLIPSE 1 trial evaluating a combination of elebsiran and tobevibart for chronic hepatitis delta. The trial met its primary endpoint with a 44% response rate (undetectable virus plus ALT normalization) at Week 48 compared to 0% in the delayed treatment group, demonstrating a favorable safety profile with no treatment discontinuations.

8:30 AM ET 8-K
Business Update OneMedNet Corp ONMD

OneMedNet Business Update

OneMedNet reported year-to-date contracted bookings of $18.76 million as of November 6, 2026, representing a significant increase over 2025 levels. The company also released a growth recap titled 'OneMedNet by the Numbers' highlighting its commercial trajectory and AI-driven real-world data platform performance.

8:30 AM ET Form 4
Insider Selling Waste Management Inc WM

Waste Management SVP-Chief Information Officer Johnson Varkey Sells $121K of Stock

Johnson Varkey, SVP-Chief Information Officer, sold 500 shares of Waste Management Inc at $242.00 a share, worth $121K in total on Nov 5, 2026. Shares held after the trade: 8,713 (-5.4%).

Value
$121K
Shares
500
Price
$242.00
Role
SVP-Chief Information Officer
Holding change
-5.4%
Trade date
Nov 5, 2026
8:30 AM ET 8-K
Stock Buyback Empery Digital Inc. EMPD

Empery Digital Stock Buyback Update

Empery Digital provided an update on its $200 million share repurchase program, disclosing the repurchase of 155,040 shares during the week ended November 6, 2026, at an average price of $2.36 per share. As of that date, the company has repurchased a total of approximately 26.7 million shares, with $49 million remaining under the current authorization. The filing also noted ongoing lease negotiations and a purchase agreement extension for a Midwest AI data center facility.

8:28 AM ET 6-K
Financial Results Ecopetrol S.A. EC

Ecopetrol H1 2026 Results: Net Income $11.3T, Up 48.5% YoY

Ecopetrol S.A. reported a significant increase in net profit for the first half of 2026, reaching 11,316 billion Colombian pesos compared to 7,618 billion in 2025, driven by higher sales revenue of 68,823 billion pesos. Despite improved operating income, the company faced substantial negative foreign currency translation adjustments in other comprehensive income, totaling 6,296 billion pesos.

Key figure
Net income $11.3T · +48.5% YoY
8:26 AM ET 10-Q
Financial Results Tonix Pharmaceuticals Holding Corp. TNXP

Tonix Pharmaceuticals Holding Q3 2026 Results: Net Loss of $53.3M, Loss Widens

Tonix Pharmaceuticals reported a significant increase in product revenue to $37.7 million for the first nine months of 2026, up from $7.7 million in 2025, though net losses widened to $134.1 million due to higher R&D and SG&A expenses. The company maintained a cash position of $162.8 million as of September 30, 2026, supported by approximately $81.7 million in net proceeds from common stock issuances during the year.

Key figure
Net loss $53.3M
8:22 AM ET 8-K
Business Update Super League Enterprise, Inc. SLE

Super League Enterprise Business Update

Super League Enterprise announced that between November 4 and November 9, 2026, it purchased 16 Bitcoin at an average price of approximately $76,892.32 per coin. The acquisition is part of the company's strategy to explore Bitcoin as a treasury reserve asset alongside its cash and cash equivalents.

8:21 AM ET 10-Q
Financial Results SHF Holdings, Inc. SHFS

SHF Holdings Q3 2026 Results: Net Loss of $979K

SHF Holdings, Inc. reported cash and cash equivalents of $4.40 million as of September 30, 2026, a decrease from $6.78 million at the end of 2025. The filing highlights significant risks including substantial doubt about the company's ability to continue as a going concern and potential impacts from the federal rescheduling of cannabis.

Key figure
Net loss $979K
8:21 AM ET 10-Q
Financial Results WhiteHorse Finance, Inc. WHF ▶ Call

WhiteHorse Finance Q3 2026 Results: Turns Profitable, Net Income $6.51M

WhiteHorse Finance, Inc. reported a net increase in net assets resulting from operations of $16.2 million for the nine months ended September 30, 2026, compared to $6.0 million in the prior year. Total investment income decreased to $45.1 million from $55.3 million, while net asset value per share improved to $11.82 from $11.68 at year-end 2025.

Key figure
Net income $6.51M
8:20 AM ET 8-K
Financial Results Neurogene Inc. NGNE

Neurogene Financial Results

Neurogene Inc. reported third quarter 2026 financial results and provided a clinical update on its NGN-401 gene therapy program for Rett syndrome. The company expects topline data from its Embolden registrational trial in the second half of 2027 and confirmed its cash runway extends into the first quarter of 2029.

Term
Q3 2026

“During the third quarter, we continued to execute across all aspects of our NGN-401 program as we advance toward potential commercialization. With topline data from the Embolden registrational trial expected in the second half of 2027, we are progressing key BLA and commercial-readiness activities, including PPQ runs that we believe remain on track for completion this year.”

Rachel McMinn, Ph.D., Founder and Chief Executive Officer
8:18 AM ET Form 4
Insider Buying Donegal Group Inc DGICB

Donegal Group Insider Donegal Mutual Insurance Co Buys $622K of Stock

Donegal Mutual Insurance Co bought 33,000 shares of Donegal Group Inc at $18.74 to $18.97 a share (average $18.83) in 3 transactions, worth $622K in total between Nov 5, 2026 and Nov 6, 2026. Shares held after the trade: 14,435,128 (+0.1%).

Value
$622K
Shares
33,000
Average price
$18.83
Holding change
+0.1%
Trade date
Nov 5, 2026 to Nov 6, 2026
8:15 AM ET 8-K
Financial Results SHF Holdings, Inc. SHFS

SHF Holdings Financial Results

SHF Holdings reported Q3 2026 revenue of $1.95 million, a 6.5% increase year-over-year, driven by a 70.2% surge in loan program income. The company's operating loss narrowed by 17.7% to $1 million as average client deposits rose to $112 million. Management noted that while the operating platform is strengthening, they remain focused on addressing challenges related to the company's capital structure and public listing.

Term
Q3 2026

“Our third-quarter results demonstrate the continued value of Safe Harbor’s established financial services platform, with higher revenue, significant growth in loan program income and increased client deposit balances.”

Terry Mendez, Chief Executive Officer of Safe Harbor

“At the same time, we recognize the challenges facing our capital structure and public listing and remain focused on evaluating solutions that preserve the value of our operating business.”

Terry Mendez, Chief Executive Officer of Safe Harbor
8:15 AM ET 8-K
Financial Results Heron Therapeutics, Inc. HRTX

Heron Therapeutics Financial Results

Heron Therapeutics reported Q3 2026 net revenue of $35.3 million, a 7.8% decrease year-over-year, driven by a decline in its Oncology franchise despite growth in Acute Care products ZYNRELEF and APONVIE. The company also announced a definitive agreement to sell substantially all of its assets to CorMedix Therapeutics, subject to stockholder approval. Heron ended the quarter with $23.4 million in cash and cash equivalents and did not provide forward financial guidance.

Counterparty
CorMedix Therapeutics
8:15 AM ET 8-K
Business Update DeFi Development Corp. DFDV

DeFi Development Business Update

DeFi Development Corp. announced it increased its Solana (SOL) treasury holdings by 8,881 SOL between November 2 and November 6, 2026, bringing its total holdings to approximately 2.61 million SOL. This marks the company's ninth consecutive week of SOL purchases as part of its strategy to accumulate and compound digital assets through staking and validator infrastructure.

8:14 AM ET Form 4
Insider Selling Donegal Group Inc DGICB

Donegal Group Sr. VP & Chief Info Officer Sanjay Pandey Sells $20.9K of Stock

Sanjay Pandey, Sr. VP & Chief Info Officer, sold 1,070 shares of Donegal Group Inc at $19.52 a share, worth $20.9K in total on Nov 5, 2026. Shares held after the trade: 8,697 (-11.0%).

Value
$20.9K
Shares
1,070
Price
$19.52
Role
Sr. VP & Chief Info Officer
Holding change
-11.0%
Trade date
Nov 5, 2026
8:14 AM ET Form 4
Insider Buying Lexicon Pharmaceuticals, Inc. LXRX

Lexicon Pharmaceuticals CEO Michael Exton Buys $50K of Stock

Michael Exton, CEO, bought 30,064 shares of Lexicon Pharmaceuticals, Inc. at $1.66 a share, worth $50K in total on Nov 6, 2026. Shares held after the trade: 328,496 (+10.1%).

Value
$50K
Shares
30,064
Price
$1.66
Role
CEO
Holding change
+10.1%
Trade date
Nov 6, 2026
8:13 AM ET 10-Q
Financial Results Burlington Northern Santa Fe, LLC

Burlington Northern Santa Fe Q3 2026 Results: Net Income $1.73B, Up 19.3% YoY

For the nine months ended September 30, 2026, BNSF reported total revenues of $19.4 billion, an 11.4% increase over the prior year, driven by growth across all freight categories. Net income rose to $4.7 billion compared to $4.1 billion in 2025, despite higher fuel and compensation expenses. The company maintained a strong liquidity position with $6.7 billion in net cash provided by operating activities during the period.

Key figure
Net income $1.73B · +19.3% YoY
8:12 AM ET 8-K
M&A Deal King Resources, Inc. KRFG

King Resources Global Signs $12.3M M&A Deal with Grand View Assets Limited

King Resources Global, Inc., through its subsidiary Heavenly Grace, entered into three purchase agreements to acquire a total of 19 collectible items for an aggregate consideration of approximately $12.34 million. The company will settle the acquisition costs by issuing common stock at a fixed price of $0.235 per share to the seller, Grand View Assets Limited.

Value
$12.3M
Counterparty
Grand View Assets Limited
8:11 AM ET 8-K
Financial Results Mereo BioPharma Group plc MREO

Mereo BioPharma Group Financial Results

Mereo BioPharma reported third quarter 2026 financial results and provided updates on its rare disease pipeline, including setrusumab for osteogenesis imperfecta and alvelestat for AATD-LD. The company ended the quarter with $26.1 million in cash, which is expected to fund operations into late-2027, excluding potential milestone payments from partners Ultragenyx and Sentynl Therapeutics.

“During the third quarter, we have made meaningful progress on our two core programs, setrusumab and alvelestat. These developments have the potential to set the stage for a transformational 2027 for Mereo, our shareholders and the patients we aim to serve.”

Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma
8:11 AM ET 10-Q
Financial Results Spruce Biosciences, Inc. SPRB

Spruce Biosciences Q3 2026 Results: Net Loss of $24M, Loss Widens

Spruce Biosciences reported a significant increase in cash and cash equivalents to $87.7 million as of September 30, 2026, compared to $48.9 million at year-end 2025. However, the company faces substantial doubt about its ability to continue as a going concern, with an accumulated deficit of $341.7 million and a need for additional financing to develop its lead product candidate, tralesinidase alfa (TA-ERT).

Key figure
Net loss $24M
8:10 AM ET 8-K
Financial Results Trinseo PLC TSEOQ

Trinseo Financial Results

Trinseo reported Q3 2026 net sales of $779 million, a 5% increase year-over-year, and an Adjusted EBITDA of $51 million. The company reported a net loss of $49 million, which included $43 million in reorganization charges related to its ongoing debt restructuring proceedings. Trinseo also announced plans to cease Latex Binders manufacturing at its Terneuzen site as part of a continuing cost optimization strategy.

Term
Q3 2026
8:08 AM ET 8-K
Financial Results Quanterix Corp QTRX

Quanterix Financial Results

Quanterix reported Q3 2026 revenue of $35.0 million, representing a 6.3% sequential increase despite market softness. The company ended the quarter with $80.7 million in cash and marketable securities while narrowing its net loss by 35.6% year-over-year to $21.6 million. Management highlighted new commercial leadership and expanded insurance coverage for its Alzheimer’s disease blood tests as key growth drivers.

Term
Q3 2026

“We delivered higher than expected topline growth in the third quarter, with revenues up 6.3% sequentially, despite continued market softness. This first step in restoring growth reflects sequential improvement across all our businesses.”

Everett Cunningham, President & CEO

“We are confident about the benefits and differentiated positioning of our research tools and diagnostics businesses, especially with new commercial leadership focused on sustained growth.”

Everett Cunningham, President & CEO
8:08 AM ET 8-K
Financial Results Opal Fuels Inc. OPAL

Opal Fuels Financial Results

OPAL Fuels reported Q3 2026 financial results with Adjusted EBITDA of $26.7 million, a 32% increase year-over-year driven by RNG production progress and Fuel Station Services growth. While net income improved to $1.7 million, the company noted that operational improvements took longer than expected, leading to a revised 2026 RNG production outlook modestly below previous guidance.

Term
Q3 2026

“Progress in RNG production, growth in Fuel Station Services, 45Z contributions and lower general and administration costs drove 32% Adjusted EBITDA growth compared to the third quarter last year.”

Adam Comora, Co-Chief Executive Officer

“While we are encouraged by the sequential production growth, which is continuing in the fourth quarter, the operational improvements took longer to implement. We now expect 2026 RNG production to be modestly below our guidance range.”

Jonathan Maurer, Co-Chief Executive Officer
8:08 AM ET 8-K
Financial Results Uniti Group Inc. UNIT

Uniti Group Financial Results

Uniti Group reported Q3 2026 consolidated revenue of $848.1 million and a net loss of $244.5 million, driven by record Kinetic consumer fiber construction and net adds. The company raised its full-year 2026 revenue guidance to a range of $3.665 billion to $3.695 billion, citing robust demand from hyperscalers and large enterprises for fiber infrastructure.

Term
Q3 2026

“We once again had a record-breaking quarter at Uniti on several fronts, highlighted by our highest level of Kinetic consumer fiber premises constructed in a single quarter of 162,000 households. We also saw the most Kinetic consumer fiber net adds ever on record, resulting in 50% of Kinetic’s total footprint now passed with fiber.”

Kenny Gunderman, President and Chief Executive Officer

“These robust bookings continue to be fueled by the unprecedented demand we are seeing from Hyperscalers, Superscalers, and increasingly traditional large enterprises for both dark and lit wave solutions. We remain well positioned as a premier insurgent fiber provider to capture substantial share of this generational growth.”

Kenny Gunderman, President and Chief Executive Officer
8:07 AM ET 10-Q
Financial Results Superior Group of Companies, Inc. SGC

Superior Group of Companies Q3 2026 Results: Net Income $2.57M, Down 6.3% YoY

Superior Group of Companies reported net sales of $146.0 million for the third quarter of 2026, a 5.4% increase over the prior year period. Net income for the nine months ended September 30, 2026, rose to $4.6 million compared to $3.5 million in 2025, despite a $2.6 million trade name impairment charge. The company significantly improved its operating cash flow to $30.7 million for the first nine months of 2026, up from $1.3 million in the prior year.

Key figure
Net income $2.57M · -6.3% YoY
8:06 AM ET 8-K
Financial Results ADC Therapeutics SA ADCT

ADC Therapeutics Financial Results

ADC Therapeutics reported Q3 2026 net product revenue of $21 million and highlighted a strategic financial restructuring completed in October that extended its cash runway into 2029. The company also noted multiple upcoming data presentations for ZYNLONTA at the ASH 2026 annual meeting.

Term
Q3 2026

“During the third quarter, we made meaningful progress toward strengthening ADC Therapeutics' balance sheet and increasing strategic optionality while advancing clinical opportunities for ZYNLONTA®.”

Ameet Mallik, Chief Executive Officer of ADC Therapeutics

“The upcoming LOTIS-7 Phase 1b and marginal zone lymphoma IIT data at ASH highlights the potential for ZYNLONTA to play an important role in the treatment of r/r DLBCL and indolent lymphomas.”

Mohamed Zaki, M.D., Ph.D., Chief Medical Officer of ADC Therapeutics
8:06 AM ET 8-K
Leadership Change LKQ Corp LKQ

LKQ Leadership Change

LKQ Corporation announced that Salvatore A. Abbate has assumed the role of President and Chief Executive Officer and joined the Board of Directors effective November 9, 2026. This appointment was accelerated from the previously announced start date of December 15, 2026, concluding the interim Office of the CEO.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.